Refine by
Neuropathy Articles & Analysis
52 news found
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
Alfa Chemistry, a leading pharmaceutical supplier, has recently announced the addition of three new APIs to its full-ranged product catalog, i.e., tofacitinib citrate, tamoxifen citrate, and epalrestat. These new products are introduced to meet the growing demands of the pharmaceutical market. Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic ...
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report that it has filed a patent application for a significant library of novel psychedelic compounds. Each compound was designed to provide specific alterations in their respective biopharmaceutical properties. The library of compounds can be selected to target ...
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 DAEJEON, South Korea, October 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology ...
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...
25 European companies from the Biotech, Medtech, Innovative Services & Digital Health sectors, committed to patients, selected by the European clusters, will present their innovation to a jury composed of HTFC’s sponsors and the HTID health innovation ecosystem. The HealthTech Innovation Days (HTID®) event, organized by the HealthTech For Care (HTFC) endowment fund, is launching ...
Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu’s current CEO, to ...
The three-year $2.97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic Pain DOYLESTOWN, PA – May 25, 2022 – Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences ...
U.S. Senator Chris Murphy (D-Conn.) announced that BioWave, based in Norwalk, CT, has been named April’s “Innovator of the Month.” BioWave is a patented smarter pain blocking technology that provides immediate, deep, long lasting relief of severe pain. BioWave devices deliver therapeutic electrical signals through skin directly to pain nerves in deep tissue to prevent pain ...
Excite Medical is proud to announce Lieutenant Colonel Todd Geohagan (ret.) as its first VP of Veteran and Military Affairs. LTC Geohagan served nearly 30 years in the United States Air Force. His experience and connection to the military community will be instrumental in expanding access to Excite’s innovative technology, while supporting those who have served, and are currently serving ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage. Similar to the company’s recently announced ...
Excite Medical, the maker of the revolutionary DRX9000™ spinal decompression machine, participated in a successful trade mission to Quito, Ecuador April 4–7, facilitated by Enterprise Florida. “It was an honor to participate in this trade mission to Ecuador, meet leaders and executives, and help spread the word about non-surgical, drug-free treatments for low back pain,” ...
Published Preclinical Data Shows KLS-13019 More Effective Than Cannabidiol (CBD) in Prevention, Reversal of Chemotherapy-Induced Peripheral Neuropathy (CIPN) DOYLESTOWN, PA – April 13, 2022 – Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible, pioneering life-sciences company devoted to addressing the opioid crisis, ...
DOYLESTOWN, PA / ACCESSWIRE / April 6, 2022 / Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today that its CEO Dean Petkanas has issued a letter to its shareholders, providing commentary on the Company’s recently achieved milestones, updates on its research and financial ...
Expansion of Pipeline Into a Third Neuronal Cell Type Builds on Existing Capabilities Intellectual Property Has Been Filed Covering Composition and Methods for Generating Auditory Neuronal Progenitors Hearing Loss Afflicts More Than 5% of the Population; More Than 430 Million People Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company ...
Nalu Medical (“NALU”) announces the “Haleakala” update, substantially upgrading both the software and firmware of their award-winning Nalu Neurostimulation System. This update adds significant new capabilities for both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). The update broadens the stimulation pulse width parameter to the widest range ...
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term ...
REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 12:30 pm Eastern ...